经审议，公司监事会及全体监事认为：为规范公司的证券投资行为，建立完善有序的投资决策管理机 制，有效防范投资风险，强化风险控制，保证公司资金、财产安全，维护投资者和公司合法权益，根据 《公司法》《证券法》《上海证券交易所股票上市规则（主板）》等有关规定，并结合《公司章程》， 同意制定《公司证券投资及金融衍生品交易管理制度（2025年4月）》。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《辰欣药业股份有限公司证券 投资及金融衍生品交易管理制度（2025年4月）》。 表决结果：3票同意，0票反对，0票弃权。 12、审议通过《公司关于提请股东大会授权董事会决定2025年中期分红方案的议案》 11、审议通过《关于制定＜公司证券投资及金融衍生品交易管理制度＞的议案》 根据《中华人民共和国公司法》《上市公司监管指引第3号一一上市公司现金分红》《公司章程》的有 关规定，结合公司实际情况，公司拟增加分红频次，由董事会提请股东会授权董事会制定2025年中期分 红方案。公司在2025年度进行中期分红的，应同时满足下列条件：1）公司当期归属于上市公司股东的 净利润为正，且累计未分配利润亦为正数；2 ...

Group 1 - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in its announcements [7][22]. - The board of directors and senior management confirm the truthfulness of the quarterly report and assume legal responsibility for any misrepresentation [2][3]. - The first quarter report for 2025 has not been audited [6]. Group 2 - The profit distribution plan for 2024 proposes a cash dividend of 3.00 yuan per 10 shares, totaling approximately 24.90 million yuan, which is 39.06% of the net profit attributable to shareholders [9][10]. - The total distributable profit for 2024 is 34.85 million yuan, after accounting for legal reserves and previous undistributed profits [9][10]. - The profit distribution plan is subject to approval at the 2024 annual general meeting [12][13]. Group 3 - The company plans to engage in financial derivatives trading in 2025 to hedge against currency and interest rate risks, with a maximum contract value of 250 million yuan [23][25]. - The board has approved the financial derivatives trading proposal, which aims to use self-owned funds for hedging purposes [26]. - The company will implement risk control measures to mitigate potential market, liquidity, and legal risks associated with financial derivatives trading [27][28]. Group 4 - The company has outlined expected related party transactions for 2025, including procurement and service agreements, with total amounts not exceeding 30 million yuan [32][38]. - The related party transactions are conducted at market prices and are not expected to significantly impact the company's financial status or independence [38][41]. - The independent directors have reviewed and approved the related party transactions before submission to the board [39].

Core Points - The company held the 19th meeting of the sixth Supervisory Board on March 26, 2025, where several key resolutions were passed regarding the 2024 annual reports and financial matters [1][2][3]. Group 1: Supervisory Board Resolutions - The Supervisory Board approved the 2024 Annual Work Report, which will be submitted to the 2024 Annual General Meeting for review [1]. - The 2024 Financial Settlement Report was also approved, reflecting the company's actual operating conditions [1]. - The company will recognize an asset impairment provision totaling 701.48 million yuan for 2024, which includes previously disclosed impairments [1]. - The 2024 Annual Report and its summary were approved, confirming that the reports accurately reflect the company's situation [1]. - The profit distribution plan for 2024 was approved, with a net profit of approximately 2.67 billion yuan attributable to shareholders [1]. Group 2: Financial and Operational Plans - The company plans to apply for a comprehensive credit limit of up to 38 billion yuan for 2025 to support its operations [6]. - A proposal to use up to 5 billion yuan of self-owned funds for entrusted wealth management in 2025 was approved [7]. - The company will engage in financial derivatives trading with a total limit of up to 6 billion USD in 2025 to manage foreign exchange risks [9]. - The company will provide guarantees for certain subsidiaries with a total limit of up to 4.03 billion yuan [12]. - The company plans to support its subsidiary, Goertek Optical Technology, with financial assistance of up to 1 billion yuan [15]. Group 3: Internal Control and Governance - The company conducted a self-evaluation of its internal control for 2024, which was approved by the Supervisory Board [6]. - The internal control system was deemed adequate and compliant with relevant laws and regulations [6]. - The company updated its internal control system to enhance management and risk prevention capabilities [19].